Advances in the Management and Treatment of Non-Hodgkin Lymphoma
This text-based CME activity provides guidance and expert recommendations on the initial diagnostic workup and therapy selection, as well as an overview of the latest data on recently approved and emerging therapeutic options for patients with B-cell non-Hodgkin lymphoma (NHL). Although recent treatment advances do not provide a cure, they do, however, provide longer remissions and improve patie...
|
|
|
Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics
Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of a...
|
Analysis of Recently Published Acute Lymphoblastic Leukemia Articles /
In this CME activity Elias Jabbour, MD, reviews some of the recent clinical developments in advanced acute lymphoblastic leukemia. We invite you to learn more about the current and emerging standards of care, as well as safety and efficacy data from the select clinical trials, in patients with acute lymphoblastic leukemia.
CONTENT AREAS
• CD19-positive ALL
• A bispecific T-cell engager...
|
|
|
Emerging Concepts in the Recognition and Management of SLE
Michelle Petri, MD, MPH, and Daniel J. Wallace, MD, FACP, MACR, provide their experience and insight into the diagnosis and management of systemic lupus erythematosus (SLE), with perspectives for both general practitioners and rheumatologists.
CONTENT AREAS
• Signs and symptoms
• Diagnosis
• Organ-threatening disease
• Non-organ-threatening disease
• Treatment goals
• Adhe...
|
|
Facing Opioid Use Disorder: Connecting Primary Care to Patients Through Best Available Evidence
Peter D. Friedmann, MD, MPH, FASAM, FACP and Jonna I. Gaberman, MD, provide their insights into the myriad challenges faced by clinicians in managing patients with opioid use disorder. The faculty discuss tools and factors to consider in the identification and assessment of persons with opioid use disorder. Treatment principles, including the importance of patient collaboration, comprehensive tr...
|
Latest Development and Expert Outlook of Management of Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal, disabling disease,
commonly associated with skin psoriasis, and estimated to affect up to 42% of the
approximately 7.5 million people in the United States with psoriasis. There remains an
ongoing challenge among clinicians to diagnose and treat patients, as well as to stay abreast
of optimal treatment strategies. In this ...
|
|
New Treatments and a New Approach to Soft Tissue Sarcoma
Soft tissue sarcomas (STS) are a diverse group of malignant tumors that occur throughout the soft tissues. Although rare, the possibility of a sarcoma must be considered in the differential diagnosis of any suspicious mass.
This CME activity provides guidance through the initial diagnostic workup and reviews the latest data of new and emerging therapeutic options for advanced, metastatic STS....
|
|
|
The New Paradigm in Atopic Dermatitis Treatment
Steven Feldman, MD, PhD, and Jonathan Silverberg, MD, PhD, MPH, provide their clinical insights into the burden of disease experienced by persons with atopic dermatitis and strategies for management. They discuss how improved understanding of pathophysiologic mechanisms has led to the availability of new topical and systemic therapies that, when integrated with other therapies, can reduce patien...
|
The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes
John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM).
CONTENT AREAS
• Unmet needs
• Experience with basal insulin/GLP-1RA
• FRC basal insulin/GLP-1RAs
• Insulin degludec/liraglu...
|
|